Stereotactic body radiation therapy versus conventional intensity-modulated radiation therapy for the treatment of prostate cancer / 中华男科学杂志

ABSTRACT

Objective@#To explore the efficacy and toxicity of stereotactic body radiation therapy (SBRT) versus conventional intensity-modulated radiation therapy (IMRT) in the treatment of prostate cancer.@*METHODS@#Forty patients with localized prostate adenocarcinoma received SBRT for 5 doses totaling 36.25 Gy (n = 20) or IMRT for 42 doses totaling 75.6 Gy (n = 20). We compared the post-therapeutic PSA levels and related toxic reactions between the two groups of patients and recorded the rates of 5-year overall survival and freedom from biochemical failure (FFBF).@*RESULTS@#The minimum level of PSA was 0.41 (0－1.25) μg/L at 2 years and 0.22 (0.1－1.4) μg/L at 3 years after radiotherapy in the SBRT group, significantly lower than 0.62 (0－2.4) μg/L and 0.47 (0－2.5) μg/L in the IMRT group (P < 0.05), while the time to the minimum PSA level was markedly shorter in the IMRT than in the SBRT group (27.9 ［1.0－40.8］ vs 33.6 ［2.7－41.6］ mo, P < 0.05). The change rate of the PSA level was remarkably higher in the SBRT than in the IMRT group at 2 and 3 years after treatment (－0.06 and －0.05 μg/L/mo vs －0.04 and －0.02 μg/L/mo, P < 0.05). No statistically significant difference was observed in the 5-year overall survival between the SBRT and IMRT groups (91.1% vs 86.7%, P = 0.158).@*CONCLUSIONS@#SBRT and IMRT are comparable in therapeutic effect and toxicity, but the former has the advantages of low cost and convenient application and is therefore more suitable as an alternative treatment of localized prostate cancer.